,21 Even the efficacies of molecular-targeted therapies, however, may differ among tumor types, such as reduced efficacy of BRAF- or KRAS-targeted therapy in colon cancer, possibly because of differences in the biology underlying the respective tumor development. This evidence concerns the gene KRAS and malignant colon neoplasm.